Half-year Report
AstraZeneca 25 July 2024 H1 and Q2 2024 results Strong underlying growth supports FY 2024 guidance upgrade, with both Total Revenue and Core EPS now expected to increase by a mid teens percentage at CER[[1]] Revenue and EPS summary [] H1 2024 % Change Q2 2024 % Change $m Actual CER $m Actual CER- Product Sales 24,629 15 18 12,452 14 18 - Alliance Revenue 939 50 50 482 42 42 - Collaboration Revenue